This study investigates advanced pancreatic cancer. It is designed to explore the effects of combining mFOLFIRINOX with anlotinib and sintilimab.
The study evaluates the safety and effectiveness of this treatment combination. Researchers will also look at how certain biomarkers may be related to treatment outcomes.
- Who can participate: Adults aged 18 to 75 with advanced pancreatic cancer may join. Participants must have no prior cancer treatments and meet health criteria.
- Study details: Participants will receive a combination of mFOLFIRINOX, anlotinib, and sintilimab. A placebo is not used in this study.